Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Energy & Commerce

Executive Summary

Chairman in the 104th Congress will not be current Ranking Republican Moorhead (Calif.), according to staffers. Moorhead will not contest Rep. Bliley's (R-Va.) bid to become full committee chair and instead will chair the House Judiciary/Patents Subcommittee. With Bliley's ascent to the chairmanship of Energy & Commerce, Rep. Bilirakis (R-Fla.) becomes the next logical choice to head the panel's Health & the Environment Subcommittee, where currently he holds the number two minority spot behind Bliley. Reps. Fields (R-Tex.) and Oxley (R-Ohio), who have more committee seniority than Bilirakis and could choose to head the Health Subcommittee, are eyeing other chairmanships, according to staffers. The Rowland/Bilirakis bill of the 103rd Congress could serve as a blueprint for more restricted health reform legislation in the house during the 104th, according to Bilirakis aides

Latest Headlines
See All
UsernamePublicRestriction

Register

PS025355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel